{"name":"Replicor Inc.","slug":"replicor-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Zadaxin","genericName":"Zadaxin","slug":"zadaxin","indication":"Other","status":"phase_1"},{"name":"pegylated interferon","genericName":"pegylated interferon","slug":"pegylated-interferon","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Viread","genericName":"Viread","slug":"viread","indication":"Chronic type B viral hepatitis","status":"marketed"}]}],"pipeline":[{"name":"Viread","genericName":"Viread","slug":"viread","phase":"marketed","mechanism":"Gag-Pol polyprotein, Reverse transcriptase/RNaseH","indications":["Chronic type B viral hepatitis","Human immunodeficiency virus infection"],"catalyst":""},{"name":"Zadaxin","genericName":"Zadaxin","slug":"zadaxin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"pegylated interferon","genericName":"pegylated interferon","slug":"pegylated-interferon","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNUW5NYVk3THJENVZudDFoZ0V2N1hBdDF6bWdHQUZsSGZremswWXNGcWN3N1RxT09ub0ZXMEx5dTNVaVRDN1JQTlhDY3RBTUstLXM5NmlLNkVCNEVtN1NIUHQ4anhHQjZ3Rm10R3l1SEFOY0NSenJ6WEo5V1VrNmNwY3RlaXFlejRjbFRwcjZLb1ZsN25nMlRFSEZuMHN5dWpUbFY0SVJaX2tjSktEd0FVYUpDcDFEWEduWXQ3UTVEeDBGWFhQZVE?oc=5","date":"2025-12-07","type":"trial","source":"PR Newswire","summary":"Replicor publishes data from its compassionate access program in HBV/HDV - PR Newswire","headline":"Replicor publishes data from its compassionate access program in HBV/HDV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQMDVqemF2SllMZ2Z3NHhzaVY1OGhUUnBaNXFTUE5UbVhXMnlVZnR5ck1yZHozLUUzNGhHaVpCelU0dmlyc0YyYVFWWEhBdlN4NzNPRzgxVnRaSUtfOTV6NmFiRld1UnhCUEI0cnctRFBJYl9ydnZqQjFSVHd3X1ptTGZoRm9VTi1pSElYaHhrcGdhOGlSdFp1c25WcVpsTzRDeFE?oc=5","date":"2024-12-30","type":"pipeline","source":"BioWorld News","summary":"Ausperbio bags $73M series B for hep B-targeting RNA therapy - BioWorld News","headline":"Ausperbio bags $73M series B for hep B-targeting RNA therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE81SXNoMjRKVmRuWldjQ1RCdTk3Tlg5UnlSU3dsNGpmZnExdEY0NkphcGpyQi11dXFQVkE4MG5HSG9WVndtSTlWOVJUX1k4dGtmeGZYODJpLUUwNzhORlZDWFlERQ?oc=5","date":"2023-04-13","type":"pipeline","source":"Precedence Research","summary":"Hepatitis D Market Size to Hit USD 1,092.71 Million by 2035 - Precedence Research","headline":"Hepatitis D Market Size to Hit USD 1,092.71 Million by 2035","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}